T he use of labeled red blood cells (RBCs) for in vivo quantitation of RBC volume and RBC survival (RCS) has advanced understanding of anemia and its treatment. RBC labeling with 51 Cr is the Food and Drug Administration's regulatory standard method for measuring short-term RBC recovery. 1 Unfortunately 51 Cr RBC labeling has shortcomings including radiation exposure and inaccuracy in quantitation of longterm RCS. Radiation concern has eliminated 51 Cr RBC kinetic studies in Europe and in vulnerable populations that include fetuses, infants, children, and pregnant women. 2 The accuracy of 51 Cr RCS is limited by variability in 51 Cr RBC elution limiting 51 Cr RCS to 30 days. 1 Biotin (vitamin B8) labeling of RBC surface proteins followed by flow cytometric enumeration overcomes both 51 Cr-labeling shortcomings. 3 Flow cytometric analysis of biotin-labeled RBCs (BioRBCs) permits accurate determination of RCS throughout more than 95% of the life span provided initial BioRBC enrichment is more than 0.5%. [4] [5] [6] Other advantages of biotin RBC labeling include the ability: 1) to concurrently and independently track RCS in vivo for multiple RBC populations labeled at separate, discrete biotin densities, and 2) to isolate BioRBCs in blood using magnetic beads for assessing biochemical and biophysical RBC changes. Despite the advantages of the biotin method, a theoretical safety issue is the occasional development of antiBioRBCs after BioRBC exposure. We have detected transient BioRBC-induced anti-BioRBC responses in four of 28 (14%) BioRBC-exposed adults using traditional tube agglutination. 7 These antibodies have not caused clinical abnormalities. 5, 8 We speculate that this is analogous to penicillin-type drug-dependent antibodies with biotin covalently attached to RBC surface proteins acting as immunogenicity enhancing haptens. 9 Although antiBioRBCs after initial BioRBC exposure have not reduced RCS, we reported an adult who experienced accelerated removal of BioRBCs when rechallenged with BioRBCs 5 years later in association with an anamnestic antiBioRBC response. 10 Although this rapid BioRBC removal did not cause abnormalities in hematologic or biotin nutritional laboratory tests, the antibody-induced shortening of BioRBC survival may render such subjects unsuitable for future BioRBC RCS studies. A robust, sensitive, and specific assay for antibodies to BioRBCs that has an objective endpoint and is easier to perform than the more subjective traditional tube agglutination 8 could expand use of BioRBCs in RBC kinetic studies. Doing so would facilitate wider adoption of the biotin RBC labeling method as an alternative to 51
Cr labeling. In addition, a better understanding of the relationship between the density and dose of the BioRBCs infused and antibody formation might lead to future approaches reducing the incidence of anti-BioRBC induction. Thus, the primary objectives of this study were: 1) to develop, characterize, and apply a commercial immunoglobulin (Ig)G gel card agglutination assay to detect BioRBCinduced and existing anti-BioRBCs; 2) to compare gel card reactivity and sensitivity with traditional tube agglutination; 8 and 3) to compare antibody induction rates to the dose of BioRBCs administered. A secondary objective was to determine the biotin label density of reagent BioRBCs that can be reliably used for screening BioRBC-na€ ıve subjects for existing anti-BioRBCs and for detecting BioRBCinduced anti-BioRBCs.
MATERIALS AND METHODS
This study received approval from the University of Iowa Committee on Research on Human Subjects.
Study subjects
Study subjects, groups of whom were tested in different laboratories, included healthy adults, hospitalized adults, and very low birthweight (VLBW) infants (birthweight < 1.5kg). Data from some study subjects have been previously reported. 4, 6, [11] [12] [13] [14] Individual subjects had variable volumes of plasma or serum available for anti-BioRBC testing; small volumes limited the scope of testing. Importantly, all subjects were initially BioRBC na€ ıve. The majority of na€ ıve subjects who received BioRBCs were screened before the study by standard RBC alloantibody and direct antiglobulin testing (DAT) and were tested for induced anti-BioRBCs approximately every 4 weeks for 12 or more weeks after BioRBC infusion.
Laboratory methods

Biotin labeling of reagent BioRBCs
Biotin density on RBC membrane has been usually defined as the ratio of the mass of the biotinylating reagent to the volume of RBCs biotinylated. 3 Consequently, BioRBC densities used in testing and infusion are designated as BioRBC-N, where N represents the ratio of sulfosuccinimidobiotin (sNHS-biotin; Pierce Chemical; mg) to RBCs (mL). The number and mass of biotins per RBC was determined as described below. For the antibody detection assays reagent BioRBCs were prepared from group O1 (to avoid possible confounding by anti-A, -B, or -A,B in subjects plasma or serum) allogeneic fresh RBCs incubated with increasing amounts of sNHS-biotin as previously described. 13 To compare the relative sensitivity of the tube and gel card 
Estimation of number of phycoerythrin molecules per cell on BioRBCs
To determine if anti-BioRBC induction is associated with the dose of biotin labels on the BioRBCs infused, we determined the total number of biotin labels infused. This was estimated as the product of the number of BioRBCs infused times the density of biotin labels per RBC. For multidensity BioRBC infusions, this is equal to the sum of the biotin labels estimated for all BioRBC populations. To estimate mean total biotin label per RBC administered for a representative BioRBC population, a flow cytometry assay utilizing streptavidin-phycoerythrin (PE) and QuantiBRITE-PE (QB-PE; Becton Dickinson) was employed. QB-PE beads contain four precalibrated bead populations with known PE molecules per bead. These generated a calibration curve. BioRBC-6 were stained to saturation with streptavidin-PE and fluorescence intensity was measured. PE molecules per BioRBC were estimated using the QB-PE standard curve and fluorescence intensity of stained BioRBCs. Because fluorescence intensity per RBC is linearly related to biotinylation reagent per mL RBCs, 13 biotin label density was then calculated as simple ratios of the biotinylation reagent masses per milliliter used in labeling individual BioRBC populations.
Tube agglutination anti-BioRBC detection method
The tube antiglobulin agglutination assay was performed as previously described. 8 Briefly, unlabeled RBCs were used to assess nonspecific agglutination; only plasma without detectable nonspecific agglutination against unlabeled RBCs were scored. K1 RBC antigen and anti-K1 served as a positive control. Agglutination strength was scored as 0 (no agglutination), 6, 1 w , 11, 21, 31, and 41. 16 
Gel card assay
Positive control. In the absence of an established antiBioRBC standard, plasma from a subject exposed to BioRBCs twice (Subject 521) that resulted in a high titer (512 at reagent density BioRBC-54) of anti-BioRBCs after the second exposure was employed. This plasma was diluted 1:100 in Diluent 2 (MTS9230, Ortho Clinical Diagnostics) as positive control. 10 Assay procedure. Like the tube antiglobulin assay, the gel card assay is based on RBC agglutination. The gel cards were used according to the manufacturer's recommendations (MTS anti-IgG Card, MTS084024, Ortho Clinical Diagnostics). Briefly, 50 mL of the reagent BioRBC-N or unlabeled RBCs (at 0.8% hematocrit in Diluent 2) was prepared from a group O1 convenience donor and layered atop the buffer in gel card microtubes. Test plasma (25 mL) was added to reagent BioRBCs or RBCs in the gel column and incubated at 378C for 30 minutes (ID-MTS incubator MTS9680, Ortho Clinical Diagnostics). Gel cards were subsequently centrifuged at 80-90 3 g for 10 minutes (ID-MTS centrifuge MT515060, Ortho Clinical Diagnostics). Doing so exposed the BioRBC/plasma mixture to the IgG antiglobulin test reagent in the gel card.
Scoring of agglutination. The BioRBC agglutination was quantified using the manufacturer's gradationspecific definitions of reactivity. Reactivity scores ranged from 0 (no agglutination) to 41 (agglutinates are trapped on the surface of the gel bed). In this study, a score of 11 (i.e., agglutination in lower half of matrix) was further subclassified into the three increasingly reactive 11 designations based on the manufacturer's photographs as follows: 1) 6 indicates a slanted pellet with a few agglutinated RBCs, 2) 1 w indicates a slanted pellet with more agglutinated RBCs, and 3) 11 indicates a disrupted RBC pellet with more agglutinated cells.
Characterization of structural specificity of anti-BioRBCs
Hemagglutination inhibition (neutralization). Hemagglutination inhibition was used to determine whether the antibody was specific to biotin, BioRBC, or both. Twenty-five microliters of plasma was incubated for 15 minutes at room temperature in the presence of soluble 16 lmol/L biotin, 8 lmol/L biocytin (a structurally related analog), biotinylated albumin, or biotinylated gelatin. Neutralized plasma was then tested by gel card.
To remove unreacted reagent and hydrolysis products, albumin stock solution was biotinylated using a threefold molar excess of sulfo-NHS biotin (Pierce Chemical) followed by dialysis. Biotinylated gelatin stock was prepared in phosphate-buffered saline as 7 mg biotinylated gelatin/mL. 17 Specificity for BioRBCs was assessed by abrogation of agglutination in the presence of biotin or its analogs. BioRBC adsorption. Antibody adsorption was used to demonstrate specificity to BioRBCs. To do this, 25 mL of test plasma was incubated with increasing amounts of BioRBCs (0.25, 2.5, and 25mL of BioRBC-512 or 21458) at 378C for 30 minutes. The reactions were then centrifuged to separate the plasma and RBCs, with the adsorbed plasma retested in the gel card assay at the initial BioRBC agglutinating reagent density. If the agglutination pattern showed reduced BioRBC dose-dependent reactivity, this indicated that the antibody was specific to BioRBCs, but not biotin.
Assay sensitivity and specificity
Comparative sensitivity of tube agglutination and the gel card agglutination assay was assessed by the titer of the positive control plasma at a fixed BioRBC reagent density, that is, BioRBC-54. Assay sensitivity in the gel card assay was determined by the lowest level of reagent BioRBC density at which induced anti-BioRBC reactivity was detected. Assay specificity of induced anti-BioRBC in the gel card assay was determined by demonstrating no plasma hemagglutination inhibition by biotin or biotin attached to other molecules.
Statistics and data management
Central tendency and variability were expressed as the mean 6 SE with 95% confidence limits provided where appropriate. The nonparametric Wilcoxon rank sum exact test was used in comparing mean values.
RESULTS
Standard RBC alloantibody and DAT
Of 26 study subjects tested for anti-BioRBCs before the autologous BioRBC transfusion, 18 were screened for RBC alloantibodies and DAT by standard blood banking assays. There were no positive results.
Performance characteristics of gel card assay Effect of anticoagulant
There were no anticoagulant or sample type effects. Comparison of reactivity among six sets of concurrently collected aliquots of undiluted and 1-in-256 diluted hightiter positive control serum, EDTA plasma, and heparinized plasma yielded identical results.
Consistency of reactivity evaluation
Using archived gel card photographs, agglutination scoring evaluated independently by two authors (RLS and JAW) was consistent.
Reproducibility. Reactivity reproducibility was also consistent in 24-gel card assays for positive control plasma diluted 1 in 100 when assayed at reagent BioRBC-54 using RBC at three study sites. In addition to these interand intraassay controls, consistent titration endpoints (i.e., the last doubling dilution showing hemagglutination) differed by acceptable variation (61 dilution) between repeat assays and between operators.
Frozen glycerolized reagent BioRBCs
Thawed glycerolized BioRBCs and unlabeled RBCs yielded identical results compared to freshly prepared BioRBCs and unlabeled RBCs (data not shown). Comparison of tube and gel card agglutination assay method results
Comparison of sensitivity
Using positive control plasma tested at reagent density BioRBC-54, anti-BioRBC reactivity was detectable at doubling dilutions up to 1 in 1024 in the gel card assay compared to only 1 in 64 in the tube assay (Table 1) .
Plasma reactivity among BioRBC-exposed subjects
Adults. Tube and gel card antibody agglutination assays were compared in a subset of eight Iowa BioRBC-exposed adults undergoing 11 autologous BioRBC survival studies.
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Testing was performed using similar reagent densities, that is, BioRBC-32 (tube) and BioRBC-32 or 64 (gel card). Scoring agreed for the two assays in 21 of the 22 plasma samples. For the one plasma sample that did not agree, the tube assay score was 6 (i.e., the lowest) while the gel card score was zero. Infants. Nineteen prestudy and end-of-study plasma samples from 11 allogeneic BioRBC-exposed infants 18 were tested in both assays using BioRBC-32 (tube) and BioRBC-54 (gel card). No plasma samples were reactive in either assay.
Gel card results for BioRBC-exposed subjects Adults: testing for induced reactivity using multiple densities of reagent BioRBCs After initial transfusion of autologous BioRBCs, 26 healthy adult subjects were tested intermittently at three sites for up to 5 months using the gel card method. Label densities, volume of BioRBCs, and total mass of biotin label infused differed substantially among the three studies and resulted in a much higher RBC biotin dose at the Iowa site (Table 2) . 5, 6 The mean total dose of biotin (as biotin label) was approximately 25-to 50-fold greater for the Iowa study compared to that in to Cincinnati or Amsterdam. With the exception of the Iowa adults, the biotin dose was less than 10% of the recommended daily intake. 19 Three of the eight BioRBC-exposed Iowa adults, but none of eight Cincinnati or 10 Amsterdam adults-all of whom were exposed to BioRBC of not more than 18 mg/mL RBCs-developed anti-BioRBC. When the 23 BioRBCexposed adults without induced antibodies were compared to the three with induced antibodies, the BioRBC dose was higher in the group who developed antiBioRBCs (p 5 0.008). These adult samples were tested using increasing reagent BioRBC densities to increase assay sensitivity. Anti-BioRBCs were first detectable only after 12 weeks in two subjects and after 16 weeks in the third (Table 3) . Using a reagent cutoff of BioRBC-256 anti-BioRBCs were detected in all three subjects who developed an immune response, that is, 100% sensitivity.
Infants: testing for induced reactivity using multiple densities of reagent BioRBCs
The study designs for the two groups of infants who had BioRBC survival studies dictated BioRBC transfusion of either two or four densities (Table 2) . 18, 20 Samples tested included 168 prestudy and monthly postinfusion plasma samples from 36 infants at reagent gel card BioRBC-54, with a subset of these tested at BioRBC-162 and BioRBC-1458 to increase the assay sensitivity. No infant developed induced anti-BioRBCs.
Gel card results for BioRBC-na€ ıve subjects Adults: reactivity tested using multiple densities of reagent BioRBCs
Among 161 healthy (i.e., not hospitalized), na€ ıve adults tested at multiple reagent BioRBC densities, 131 (81.4%) were nonreactive at all BioRBC densities, and 30 (18.6%) showed varying degrees of reactivity starting at BioRBC-162 (Table 4 ). The percentage of samples with detectable existing anti-BioRBCs increased as reagent BioRBC density increased. Most subjects with reactive plasma demonstrated increases in strength of reactivity with increasing density. No anti-biotin immune response was detected in any of the five laboratory workers regularly performing RBC biotinylation. For the eight Iowa adults later transfused with BioRBCs, none of the prestudy na€ ıve plasma samples were reactive at reagent densities less than or equal to BioRBC-256. 13 In contrast, six of these same eight prestudy na€ ıve plasma samples were reactive when tested at reagent densities more than BioRBC-256, including two who developed induced anti-BioRBCs and four who did not.
Adults: expanded testing to evaluate prevalence of anti-BioRBCs in na€ ıve populations
In addition to characterization of reagent BioRBC density on reactivity of plasma from na€ ıve healthy adults, an additional 964 plasma samples were screened for the presence of existing anti-BioRBCs. For this, samples were from deidentified hospitalized BioRBC-na€ ıve adult subjects using a reagent density of BioRBC-140. Of these, four (0.4%) were reactive. Further multidensity testing demonstrated that one of these four na€ ıve reactive subjects was reactive beginning at BioRBC-18 (21 reactivity) and two more became first reactive at BioRBC-54 (21 and 11 reactivity). Combined with the two healthy na€ ıve hospitalized subjects demonstrating existing reactivity at BioRBC-162, the pooled reactive rate for na€ ıve samples tested at either BioRBC-140 or BioRBC-162 was 0.5% (six of 1125 plasma samples).
Infants: reactivity tested using multiple densities of reagent BioRBCs
In contrast to na€ ıve adults, none of 83 na€ ıve VLBW infant study subjects demonstrated plasma reactivity using reagent BioRBC-54. A subset of 46 of these 83 na€ ıve neonates had sufficient plasma for additional testing at BioRBC-162 and BioRBC-1458; none were reactive.
Characterization of binding specificity of antiBioRBC
Agglutination results of RBC labeling using DNP-RBCs as the reagent cells
The high-titer positive control plasma caused the BioRBCs to agglutinate in a dose-dependent fashion; that is, the higher-density BioRBCs produced greater agglutination. The DNP-RBCs did not produce any agglutination at reagent densities up to a DNP density equivalent to BioRBC-486.
Hemagglutination neutralization (inhibition) by biotin, biocytin, and biotinylated proteins
Using the gel card agglutination inhibition assay, induced anti-BioRBCs from Subjects 521, 526, and 528 were not neutralized by 16 lmol/L biotin in solution; additional testing of plasma from Subject 521 also showed no neutralization by 8 lmol/L biocytin or biotin attached to albumin or gelatin. In contrast, of the four hospitalized na€ ıve subjects with existing anti-BioRBCs who were reactive at BioRBCs of not more than 140 or below, all were neutralized with biotinylated albumin and biotinylated gelatin. Three of these were neutralized with biotin and one was not. Similarly, three were neutralized with biocytin and one was not. Of the 29 na€ ıve, healthy, nonhospitalized subjects who exhibited plasma reactivity at reagent BioRBCs of at least 162 and who had sufficient plasma for additional testing, reactivity sometimes depended on the donor providing the BioRBCs. When the plasma reactivity could be reproduced, neutralization was observed with most of the biotin or biotin containing compounds.
Adsorption of anti-BioRBCs by prior exposure to BioRBC
Reactive plasma samples from na€ ıve (n 5 5) and BioRBCexposed subjects (n 5 2) demonstrated a dose-dependent reduction-or elimination-of gel card reactivity after incubation with increasing volumes of BioRBC-1458.
DISCUSSION
Using commercial gel cards, we developed, characterized, and applied an assay for detecting plasma anti-BioRBCs in humans. This is important because of the limitations of RCS measurements using radioactive 51 Cr labeling that include variable rates of 51 Cr RBC elution and radiation exposure. 3, 7 Here we present evidence that a BioRBCadapted commercial gel card agglutination assay provides a more simple, more rapid, more reliable, less subjective, and more sensitive means for assessing induced antiBioRBC immune responses relative to the traditional tube agglutination method. 8 This method can also detect existing anti-BioRBCs among na€ ıve subjects. Employment of screening and follow-up monitoring for their exclusion from initial and subsequent RBC kinetic studies, respectively, will help reduce the chance of artifactually reducing BioRBC survival, thereby enhancing the validity of RBC kinetic determinations. Based on these findings, we speculate that BioRBC transfusion-induced anti-BioRBCs are the result of the covalent modification of biotinylated RBC surface protein amino acid (primarily lysine) residues. This enhances RBC immunogenicity 21, 22 similar to alloimmunization of intrinsic RBC antigens. 9 Our DNP experiments suggest that induced anti-BioRBCs are highly specific to the biotin moieties and that modified RBC surface proteins are not in general epitopes for these antibodies. In screening potential participants for exclusion from RBC kinetic studies, we recommend that a gel card BioRBC-256 reagent density be used. This recommendation is based on achieving adequate sensitivity to identify all three subjects in whom plasma anti-BioRBCs were detectable and on the observation that subjects testing positive pre-BioRBC dosing at gel card reagent BioRBCs of more than 256 mg/mL were not more likely to later develop induced antibodies. The recommendation of BioRBC-256 for screening may ultimately prove to be higher than necessary. This is based on too few-only three-subjects who developed antiBioRBCs, often with insufficient available plasma for confirmatory testing and with no plasma available more than 20 weeks after BioRBC dosing in some subjects (Table 3 ). An important finding of this study was the significant association of BioRBC dose with induction of antiBioRBCs. While based only on three subjects who developed antibodies, none of the 18 subjects dosed with BioRBC-6 or BioRBC-18 developed antibodies. This dose dependence is mechanistically plausible based on other preclinical 23 and clinical studies 24, 25 of RBCs in which increasing density of RBC surface antigens increases the likelihood of developing alloimmunization once a threshold is exceeded. Thus, a lower total dose of biotin label, or a lower density of biotin label per RBC, may reduce the immunogenic potential.
Here we report antibody specificity and timing of sensitization post-BioRBC exposure. Both existing and induced anti-BioRBCs were characterized both by neutralization of hemagglutination using soluble biotin and structurally related compounds and also by antibody adsorption using reagent BioRBCs. Plasma samples from BioRBC-na€ ıve subjects could be neutralized by soluble biotin, biocytin, biotinylated albumin, and biotinylated gelatin. This was in contrast to most BioRBC-induced reactive plasma that could not, thus suggesting that there are structural differences in their typical epitopes. We speculate that existing and induced anti-BioRBCs bind to the biotin moieties per se, but that at least some induced BioRBC antibodies appear to recognize an additional epitope (perhaps the linker or the biotinylated amino acid residues) and thus still bind to BioRBCs causing hemagglutination (i.e., gel card reactivity) despite prior incubation with biotin, biocytin, or a biotinylated protein. Yet the induced anti-BioRBCs did not bind to RBCs derivatized with the same linker but in which the biotin was replaced with DNP. While we speculate that the linker alone is not a strong enough epitope to bind anti-BioRBCs, steric hindrance from DNP cannot be ruled out. The origin of the existing anti-BioRBCs we identified is unknown. Possibly these individuals may have had prior environmental or dietary exposure to biotin or a related compound to invoke an immune response.
Notwithstanding these limitations, this study provides indirect evidence that use of BioRBCs is safe and accurate for assessing human RBC kinetics. This interpretation of safety rests primarily on lack of laboratory or clinical adverse effects evidenced by: 1) induced anti-BioRBC production after initial BioRBC exposure has had no detectable effect on hematologic variables or on biotin nutritional status 10 and 2) clinical features of hemolytic reactions have not been seen-presumably because the volumes of BioRBCs transfused for RBC kinetic studies are small (approx. 0.40 mL of BioRBC/kg body weight) and unlikely to cause a clinically significant transfusion reaction, even if the entire BioRBC transfusion was acutely hemolyzed. This inference is supported by copious data, including mistaken transfusion of ABO-incompatible RBCs, and the presence of RBC incompatibility or mismatch in the setting of allogeneic peripheral blood stem cell transplantation. 26 Because premature infants lacked naturally existing anti-BioRBCs and did not develop induced anti-BioRBCs, safety issues in this study population appear even less concerning. Regarding the determination of RBC volume and short-and long-term RCS, induced anti-BioRBCs do not affect the accuracy of initial RBC kinetic studies. This is likely attributable to antiBioRBCs not appearing until 3 to 4 months after dosing. 5, 8 We conclude that the performance of the gel card agglutination assay makes it preferable to its predecessor, the tube agglutination assay, for detecting plasma antiBioRBCs. The gel card assay is more sensitive, less operator dependent, and can be performed using readily available commercial reagents and equipment. 27 In applying the gel card assay in detecting anti-BioRBCs in population BioRBC kinetic studies, our current sensitivity and specificity-based recommendation is to use a reagent density of not more than BioRBC-256. Because few adult study subjects had existing or induced anti-BioRBC limited sample volume, the association of anti-BioRBC induction and low biotin dose of the transfused BioRBCs must be viewed as tentative. If confirmed, this putative association between BioRBC dose and anti-BioRBC induction implies that dosing with low total BioRBC dose or density will reduce-or perhaps eliminate-this antibody induction. Because we predict that application of the population biotin RBC labeling method will advance transfusion medicine and enhance understanding of hematologic disorders and RBC physiology, we speculate that development of the gel card assay will be particularly useful.
